Table 1.

Inhibitory effects of CC-5079 on proliferation of various cancer cell lines

Cell lineTumor originP-gp *Growth inhibition, IC50 (mean ± SD, nmol/L)
TaxolColchicineCC-5079
HT29Colon0<0.102.8 ± 0.3121 ± 0.23
HT-144Melanoma0<0.1031 ± 0.2250 ± 4.2
HCT-116Colon00.30 ± 0.02620 ± 1.817 ± 1.1
A549Non–small cell lung cancer01.2 ± 0.222.0 ± 0.1625 ± 2.3
NIH:OVCAR-3Ovary0<0.105.8 ± 0.654.1 ± 0.23
PC-3Prostate03.0 ± 0.3219 ± 2.225 ± 0.12
HCT-15Colon+150 ± 4591 ± 4.521 ± 0.21
MCF-7Breast00.50 ± 0.123.0 ± 0.656.9 ± 0.34
MCF-7/AdrBreast+7,100 ± 520920 ± 8817 ± 1.1
MES-SAUterus01.2 ± 0.112.1 ± 0.2211 ± 1.3
MES-SA/MX2Uterus+2,800 ± 33031 ± 0.2612 ± 0.88
MES-SA/Dx5Uterus+1900 ± 3101100 ± 9816 ± 1.3
  • * P-gp levels were reported previously and confirmed by flow cytometry after staining cells with anti-P-gp-FITC antibody. Scoring code: 0, not detected; +, high-level expression.

  • Cells were grown in the presence of test compounds for 3 days, and the growth was assessed by [3H]thymidine incorporation. All experiments were done at least in two replicates, and IC50s were calculated from dose-response curves by nonlinear regression analysis.